Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

Costas Lallas, MD
Published: Monday, May 22, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

The checkpoint inhibitors are how the body recognizes itself, explains Lallas. Checkpoint inhibitors allow T cells to be activated, and increase cellular response against malignancies, which is a reason why immunotherapy has been efficacious.

Hypothetically, if you can combine regimens that ramp up the immune system maximally to fight these malignancies, it is going to be beneficial, states Lallas.
 


Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

The checkpoint inhibitors are how the body recognizes itself, explains Lallas. Checkpoint inhibitors allow T cells to be activated, and increase cellular response against malignancies, which is a reason why immunotherapy has been efficacious.

Hypothetically, if you can combine regimens that ramp up the immune system maximally to fight these malignancies, it is going to be beneficial, states Lallas.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x